Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...

Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...

Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage ...

Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have ...

Mapping the genomes of the bacteria responsible for yaws, a debilitating childhood disease, has uncovered new insights into ...

Researchers from Children's Hospital of Philadelphia (CHOP) have developed a method to help cancer immunotherapies reach ...

Our team of savvy editors independently handpicks all recommendations. If you make a purchase through our links, we may earn a commission. Deals and coupons were accurate at the time of publication ...

CHICAGO, IL – A police bodycam video showing the arrest of an Indian tourist at a Target store in suburban Schaumburg has gone viral, triggering a wave of commentary on social media and opening a ...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated ...

Janus Kinase inhibitors (JAKis) are approved for the management of several chronic inflammatory diseases, from rheumatic conditions, to dermatological and ...